

Supporting Information

Discovery of novel PDE9A inhibitors with antioxidant activity for treatment of Alzheimer's disease

Chen Zhang^{a, †}, Qian Zhou^{a, †}, Xu-Nian Wu^a, Ya-Dan Huang^a, Jie Zhou^a, Zengwei Lai^{a,*}, Yinuo Wu^{a,*} and Hai-Bin Luo^{a, b}

^a School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, PR China

^b Collaborative Innovation Center of High Performance Computing, National University of Defense Technology, Changsha 410073, China

^c State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Guangxi Normal University, 15 Yu Cai Road, Guilin 541004, China

† These authors contribute equally.

*Corresponding authors: wyinuo3@mail.sysu.edu.cn (Y. Wu). or 2860879@sina.com (Z. Lai)

Content

1. Figure S1-S8 and Table S1 -----	S2
2. ¹ HNMR and ¹³ CNMR of compounds 1a-1l , 2 and 3 -----	S9




Figure S1: Designed compounds with different linkers.

Table S1. The Docking Score values and IC₅₀ of compounds **1a-1l**, **2**, and **3**.

Compound	Docking Score ^a	IC ₅₀ ± SD (nM) ^b
3	3.7284	>500 ^c
1e	5.6790	>200 ^c
1a	5.8646	126 ± 15
1l	6.2419	57±4
1k	6.3890	130±6
1d	6.7393	83± 11
1b	6.9738	64± 2
1j	7.0099	186±7
1h	7.1075	56±7
2	7.1897	25±4
1f	7.2400	190±7
1c	7.2997	65± 4
1i	7.8117	133±22
1g	8.6352	63± 3

^a Docking Score values are given by the total_score of Surflex-Dock method embedded in Tripos Sybyl 2.0.

^b IC₅₀ values are given as the mean of three independent determinations.

^c The IC₅₀ values of **1e** and **3** are treated as 200 and 500 nM for the correlation with Docking Score values.




Fig. S2. The correlation between Docking Score values and IC₅₀ values of compound **1a-1l**, **2**, and **3**.




Figure S3: Binding modes of compound **1a**, **1c**, **1d** and **1e**.




Figure S4: Binding modes of compounds **1b**, **1j**, **1k** and **1l**.




Figure S5: Binding modes of compounds **1f**, **1g**, **1h** and **1i**.




Figure S6: Binding modes of compounds **2** and **3**.




Figure S7: The RMSD plots of compounds **1h** and **2**.







Figure S8: Cell viability of compounds **1h** and **2**. A) without cell and compounds A) without cell but compounds were added at 100μM



^1H and ^{13}C NMR of M-6





¹H and ¹³C NMR of **1a**




^1H and ^{13}C NMR of **1b**





^1H and ^{13}C NMR of **1c**





^1H and ^{13}C NMR of **1d**





¹H and ¹³C NMR of **1f**





^1H and ^{13}C NMR of **1g**





^1H and ^{13}C NMR of **1h**





^1H and ^{13}C NMR of **1i**





^1H and ^{13}C NMR of **1j**





^1H and ^{13}C NMR of **1k**



^1H and ^{13}C NMR of **11**



^1H and ^{13}C NMR of 2



^1H and ^{13}C NMR of **3**

